The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | An exciting time for CAR T-cell therapy: promising results for B-ALL, nHL and CLL
Here, Stanley Riddell, MD, of Fred Hutchinson Cancer Research Center, Seattle, WA., speaks about the promising results with CD19-targeted CAR T-cell therapy for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (nHL) and chronic lymphocytic leukemia (CLL). Dr Riddell also addresses the issue of relapse in certain populations of patients, stressing the need to identify alternative targets and improve persistence. Dr Riddell was speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA).
